POMP and cancer: Thus, we investigated whether the NRF3-POMP axis affects the resistance of cancer cells to two distinct proteasome inhibitor anticancer agents: the proteasome inhibitor BTZ and the ubiquitin-activating enzyme E1 inhibitor TAK-243 (17, 19).